mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, and Egis Pharmaceutical PLC, today announced a new strategic license agreement for the commercialization of biosimilar candidates across key Central and Eastern European markets, including Hungary, Poland, Czech Republic, Slovakia, Romania, Bulgaria, Latvia, and Lithuania. The partnership also includes the option to expand to additional territories in the future.

Under the terms of the agreement, mAbxience will hold the marketing authorization for the biosimilars in these regions, while Egis will manage the commercialization and marketing activities. This collaboration underscores the commitment of both companies to broaden access to essential, high-quality therapies in markets where affordability and accessibility are critical.

José Ramón Millán, Global Partnering & Portfolio Director at mAbxience, commented on the partnership: "We are delighted to partner with Egis to bring our biosimilar candidate to patients in these important Eastern European markets. This agreement strengthens our presence in the region and reaffirms our dedication to ensuring that life-saving treatments are accessible and affordable. We look forward to working closely with Egis to make a significant impact on patient care."

Dr. Klara Marton, Business Development Director from Egis added: "This collaboration with mAbxience enables us to deliver high value  treatments to patients across Central and Eastern Europe. We are proud to join forces with a trusted partner like mAbxience, whose commitment to high-quality, affordable healthcare solutions aligns with our mission to improve patient access and patient outcomes in our region."

This agreement marks a significant milestone in mAbxience’s expansion into new markets and further reinforces its commitment to providing accessible, high-quality biosimilar therapies to patients worldwide. 

^{About mAbxience}

^{mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.}